SFDA Identifies Unqualified Drugs
January 21, 2009 |
Print
|
Email
|
Comments | Category: Health
The Chinese State Food and Drug Administration said in the third drug quality report of 2008 that it had identified 13 substandard drugs while conducting a spot-check of pharmaceuticals.
The drugs checked were the two biological products Japanese Encephalitis live attenuated vaccine and measles vaccine; and four drugs Qing Kai Ling Injection, theophylline, nimodipine, and nitroglycerin tablets. SFDA said the 103 samples of the two vaccines they examined, Japanese Encephalitis live attenuated vaccine and measles vaccine, were all up to standard. However, of the 295 theophylline samples, four made by Jinzhou Jiutian Pharmaceutical Company with the series number of 20071001 and five made by Sichuan Xicheng Pharmaceutical Company with the series number of 080101 were substandard.
SFDA spot-checked 862 Nimodipine samples. Of these, four were found to be substandard and they were all said to be made by Chongqing Kerui Pharmaceutical Company with the series number of 070501.
All the 266 Qing Kai Ling Injection samples and 328 nitroglycerin tablets samples were reported to be up to standard.
Leave A Comment:
-
Education
- HTC Chairman Sets Up New Charitable Foundation
- American Medical Company Plans Physician Training With New Beijing Outpost
- Chinese Universities Sign Education Deals With Christian American School
- New "100,000 Strong Initiative" Hopes To Build U.S.-China Golden Bridges
- Best Buy Creates Education Fund In China
-
Energy & Cleantech
-
Environment
-
Giving
-
Happenings
-
Health
- Legal Action Against Counterfeit Cigarettes In America Could Impact Chinese Makers
- New Collaboration In China Aims To Provide Low-cost Medicines
- Carrefour's Beijing Stores Gain Green Market Certification
- American Medical Company Plans Physician Training With New Beijing Outpost
- New Healthcare Chief Named For GE China
-
Labor
-
Law & Order
-
Viewpoints
- Companies Can Help In The March Towards Better Consumer Rights In China
- CSR Review: Companies Have More Opportunities To Develop In China
- How Far Can Chinese Companies Take Corporate Social Responsibility?
- CSR Review: Companies Focus On Sustainability In China During Downturn
- Global Financial Woes May Impact Corporate Social Responsibility In China







